Search: onr:"swepub:oai:DiVA.org:uu-229388" > Immunotherapy targe...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03053naa a2200421 4500 | |
001 | oai:DiVA.org:uu-229388 | |
003 | SwePub | |
008 | 140806s2014 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2293882 URI |
024 | 7 | a https://doi.org/10.2217/IMT.13.1622 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a for2 swepub-publicationtype |
100 | 1 | a Lindström, Veronicau Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)veher764 |
245 | 1 0 | a Immunotherapy targeting alpha-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders |
264 | 1 | c 2014 |
338 | a print2 rdacarrier | |
520 | a Immunotherapy targeting a-synuclein has evolved as a potential therapeutic strategy for neurodegenerative diseases, such as Parkinson's disease, and initial studies on cellular and animal models have shown promising results. alpha-synuclein vaccination of transgenic mice reduced the number of brain inclusions, whereas passive immunization studies demonstrated that antibodies against the C-terminus of alpha-synuclein can pass the blood-brain barrier and affect the pathology. In addition, preliminary evidence suggests that transgenic mice treated with an antibody directed against alpha-synuclein oligomers/protofibrils resulted in reduced levels of such species in the CNS. The underlying mechanisms of immunotherapy are not yet fully understood, but may include antibody-mediated clearance of pre-existing aggregates, prevention of protein propagation between cells and microglia-dependent protein clearance. Thus, immunotherapy targeting alpha-synuclein holds promise, but needs to be further developed as a future disease-modifying treatment in Parkinson's disease and other alpha-synucleinopathies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng |
653 | a alpha-synuclein | |
653 | a antibody | |
653 | a immunization | |
653 | a immunotherapy | |
653 | a Parkinson's disease | |
700 | 1 | a Ihse, Elisabetu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)elihs048 |
700 | 1 | a Fagerqvist, Thereseu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)thewa743 |
700 | 1 | a Bergström, Joakimu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)joakberg |
700 | 1 | a Nordstrom, Eva4 aut |
700 | 1 | a Moller, Christer4 aut |
700 | 1 | a Lannfelt, Larsu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)lalan021 |
700 | 1 | a Ingelsson, Martinu Uppsala universitet,Geriatrik4 aut0 (Swepub:uu)maing121 |
710 | 2 | a Uppsala universitetb Geriatrik4 org |
773 | 0 | t Immunotherapyg 6:2, s. 141-153q 6:2<141-153x 1750-743Xx 1750-7448 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-229388 |
856 | 4 8 | u https://doi.org/10.2217/IMT.13.162 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view